An interventional study of LP28 capsule and Placebo Capsule in Common Cold, Immunity and Probiotic, sponsored by Synbio Tech Inc.. Completed at 2 sites in Taiwan. Open to participants aged 50 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-28.
Sponsored by Synbio Tech Inc. · Not applicable, Interventional, and Prevention
Due to the increasing attention on aging-related health issues, this study focuses on the elderly population as participants. The aim is to investigate whether supplementation with Lactobacillus plantarum LP28 can effectively enhance immunity, reduce the frequency and severity of common cold infections, and ultimately promote overall health in the elderly.
219 studies on the registry are indexed under Common Cold; 23 are open to participants now.
This study's enrollment of 102 is below the median of 150 across 184 interventional studies indexed under Common Cold.
Browse Common Cold studies →Synbio Tech Inc. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects will take two capsule of the experimental group(LP28 capsule) within 30 minutes before breakfast and dinner each day.
Dietary Supplement: LP28 capsule
Subjects will take two placebo capsule within 30 minutes before breakfast and dinner each day.
Dietary Supplement: Placebo Capsule
LP28 capsule : 5.0×10\^9 CFU/capsule
Maltodextrin
WURSS-24
The WURSS-24 (Wisconsin Upper Respiratory Symptom Survey-24) is a questionnaire designed to assess the impact of upper respiratory tract infections, such as the common cold, on daily life and health. It includes 24 questions covering symptoms (e.g., cough, runny nose, fatigue) and how they affect daily activities, work, and social interactions. Patients rate each item on a scale from 0 (no problem) to 7 (severe problem).
Time frame: From enrollment to the end of treatment at 12 weeks (measure daily)
Immune cell ratio
Blood samples were collected, and the proportions of immune cells were analyzed using flow cytometry, including: (1) CD3+/lymphocyte, (2) CD4+/CD3+, (3) CD8+/CD3+, and (4) CD56+CD16+/lymphocyte.
Time frame: From enrollment to the end of treatment at 12 weeks (measure every 6 weeks)
NK cell activity
Peripheral blood mononuclear cells (PBMCs) were isolated, and magnetic bead-based separation was used to deplete non-NK cells. The K562 human immortalized myelogenous leukemia cell line was then used as target cells, and the proportion of K562 cells lysed by NK cells was measured as an indicator of NK cell activity.
Time frame: From enrollment to the end of treatment at 12 weeks (measure every 6 weeks)
Cytokines measurement
Plasma was collected, and cytokine concentrations were analyzed using enzyme-linked immunosorbent assay (ELISA). The detection items included IL-4, IL-6, IL-12, IFN-γ, CRP and TNF-α.
Time frame: From enrollment to the end of treatment at 12 weeks (measure every 6 weeks)
sIgA
Saliva samples were collected, and Secretory immunoglobulin A (sIgA) concentrations were analyzed using enzyme-linked immunosorbent assay (ELISA).
Time frame: From enrollment to the end of treatment at 12 weeks (measure every 6 weeks)
α-amylase
Saliva samples were collected, and α-amylase concentrations were analyzed using enzyme-linked immunosorbent assay (ELISA).
Time frame: From enrollment to the end of treatment at 12 weeks (measure every 6 weeks)
GSRS questionnaire
The Gastrointestinal Symptom Rating Scale (GSRS) is a questionnaire used to evaluate the severity of gastrointestinal symptoms. It includes questions on five key areas: abdominal pain, reflux, diarrhea, indigestion, and constipation. Patients rate their symptoms on a 7-point Likert scale, where higher scores indicate more severe symptoms.
Time frame: From enrollment to the end of treatment at 12 weeks (measure weekly)
Defecation frequency and stool pattern
Defecation frequency was recorded, and stool characteristics, including shape, consistency, and color, were documented using the Bristol Stool Chart.
Time frame: From enrollment to the end of treatment at 12 weeks (measure weekly)
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Synbio Tech Inc.